Trial site
Somed Cr Sp. z o.o. sp.k.
Lodz, 90-368, PolandEU-13 widening countryNot linked to an institution yet
- 8running trials
- 5closed trials
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 23 trials
- Status
- Active, not recruiting5 trials
- Completed5 trials
- Recruiting2 trials
- Not yet recruiting1 trial
- Lead sponsor
- MoonLake Immunotherapeutics AG2 trials
- Argenx1 trial
- AstraZeneca1 trial
- AstraZeneca AB1 trial
- Bristol-Myers Squibb1 trial
- and 7 more
Running trials
Recruiting
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
2025-523670-17-00· Phase 3· AstraZeneca AB· Source
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574· Phase 2· Hoffmann-La Roche· Source
Not yet recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus
2024-510584-37-00· Phase 2· Zenas Biopharma (USA) LLC· Source
Active, not recruiting
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2)
2022-500700-22-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source
Active, not recruiting
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202· Phase 3· Bristol-Myers Squibb· Source
Active, not recruiting
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
NCT04877691· Phase 3· AstraZeneca· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)
NCT06684847· Phase 3· Argenx· Source
Completed
A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® Sourced from the European Union in Postmenopausal Women with Osteoporosis
2024-512417-41-00· Phase 3· Xentria Inc.· Source
Completed
Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis
2023-503790-37-00· Phase 3· Curateq Biologics Private Limited· Source
Completed
Safety and Efficacy of RHH646 for Knee Osteoarthritis
NCT05816395· Phase 2· Novartis Pharmaceuticals· Source
Completed
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971· Phase 3· LG Chem· Source
Report an error